Analysis of gene polymorphism in hepatocellular carcinoma patients treated with sorafenib therapy

Analysis of gene polymorphism in hepatocellular carcinoma patients treated with sorafenib therapy - AGHCs

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016431

Enrollment

150

Registered

2015-02-06

Start date

2015-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heoatocellular carcinoma

Interventions

sorafenib therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosed hepatocellular carcinoma patients treated with sorafenib therapy, discontinued sorafenib therapy, or intended to treat with sorafenib therapy 2. Extrahepatic metastasis is no object. 3. Child-Pugh class A-B(7) 4. Good reserved function of main organs (bone marrow, kidney, and heart) (1) WBC >/= 2000/mm3 (2) Plt >/= 5x104/mm3 (3) Hb >/= 8.0g/dL (4) creatinine < 2mg/dL (5) Heart function except exclusion criteria 5. Informed consentwas obtained.

Exclusion criteria

Exclusion criteria: 1. Following serous comlicating diseases, except for chronic hepatitis and liver cirrhosis: a) Renal failure with blood or peritoneal dialysis b) Heart failure >/= NYHA class III, serious ischemic herat disease, and serious arhythmia c) uncontrolled hypertension d) brain tumors 2. Past or present history of malignant tumors except for HCC 3. Past history of allergy in iodine or contrast agent 4. Inadequate patient judged by a doctor

Design outcomes

Primary

Measure	Time frame
Relationship between side effects and gene polymorphism	—

Secondary

Measure	Time frame
Relationship between prognosis and gene polymorphism	—

Countries

Japan

Contacts

Public ContactSaeki Issei

Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology

issaeki@yamaguchi-u.ac.jp0836-22-2241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026